ArgentinaTuberculosis profile
Population  2016 44 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.6 (0.58–0.63) 1.4 (1.3–1.4)
Mortality (HIV+TB only) 0.064 (0.031–0.11) 0.15 (0.07–0.25)
Incidence  (includes HIV+TB) 11 (9.2–12) 24 (21–28)
Incidence (HIV+TB only) 0.59 (0.38–0.85) 1.4 (0.87–1.9)
Incidence (MDR/RR-TB)** 0.44 (0.29–0.58) 0.99 (0.66–1.3)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.57 (0.49–0.66) 3.5 (3–4) 4.1 (3.5–4.6)
Males 0.59 (0.51–0.68) 6 (5.1–6.9) 6.6 (5.6–7.6)
Total 1.2 (1–1.3) 9.5 (8.1–11) 11 (9.2–12)
TB case notifications, 2016  
Total cases notified 10 592
Total new and relapse 10 023
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 19%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 65%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 94% (82–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.06 (0.05–0.07)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 592 31%
          - on antiretroviral therapy 167 28%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  370
(240–500)
Estimated % of TB cases with MDR/RR-TB 2.3% (1.1–3.6) 18% (9.5–27)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs   112
Laboratory-confirmed cases MDR/RR-TB: 114, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 114, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 47% 9 854
Previously treated cases, excluding relapse, registered in 2015 38% 956
HIV-positive TB cases registered in 2015 28% 655
MDR/RR-TB cases started on second-line treatment in 2014 26% 121
XDR-TB cases started on second-line treatment in 2014 40% 5
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 4.6
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data